Anthrax
Elusys' Anthrax Therapeutic, Anthim, Selected To "100 Great Investigational Drugs" List By R&d Directions
Published in Lab Business Week, May 13th, 2007
Elusys Therapeutics, Inc., a biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections, today announced that Anthim(tm), the company's anthrax antibody therapeutic, has been selected to R&D Directions' list of "100 Great Investigational Drugs." For a product to be selected to this independent list, it must show substantial potential in a major or growing therapeutic area and be under active development.
Elizabeth Posillico, Ph.D., President and CEO of Elusys Therapeutics, commented on the announcement, "This is a real honor and we are delighted that Anthim is counted among the 100 Great Investigational Drugs. I speak for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2007-05-13)
More Articles from Lab Business Week
- Axon Labs, Inc.
Axon Labs Names David P. Dickinson as Chief Executive Officer - Bird Flu
Carrington Subsidiary Delsite Biotechnologies Secures Antigen for Phase I Clinical Trial of Nasal Powder Influenza Vaccine - Clostridium
Reports summarize clostridium study results from Kyoto Biken Laboratories, Inc. - Dermatology
Stiefel Laboratories Moves to Solidify, Enhance Its Leadership Position in Dermatology - Drug Development
Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval to Market Generic Ambien - Drug Development
Dr. Reddy's Announces the Launch of Zolpidem Tartrate Tablets - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
